ArticleStem cells translational medicine2025
Fibroblast Growth Factor 2-engaged cell spheroid for stem cell therapy: role of Interleukin 8 in the immune-modulatory effectiveness in the critical limb ischemia model.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundStem cell therapy has emerged as a promising approach for treating critical limb ischemia (CLI), a condition caused by atherosclerosis that results in reduced blood flow and limb necrosis. However, the underlying therapeutic mechanisms involving factors secreted from stem cells are still in the early stages of exploration. This study focuses on investigating the tissue regenerative effects of interleukin-8 (IL8) secreted from cell spheroids.
methodsHuman adipose-derived stem cells (hASCs) were cultured on FGF2-tethered surfaces to form spheroid (FECS-Ad). A murine CLI model was established through femoral artery dissection, followed by the injection of various treatments, including PBS, hASC, FECS-Ad, IL8-silenced FECS-Ad, and recombinant IL8.
resultsComparative analyses revealed that FECS-Ad injection resulted in a higher percentage of salvaged limbs, but these effects were attenuated when IL8 was silenced in FECS-Ad. Immunofluorescence staining, flow cytometry analysis and RT-qPCR of M1 and M2 macrophage markers demonstrated that IL8 has the ability to polarize macrophages to M2 type. Notably, FECS-Ad injection reduced apoptotic markers (caspase 8 and TUNEL) in ischemic tissues, whereas IL8 knockdown in FECS-Ad increased the proportion of apoptotic cells. FECS-Ad injected tissues showed larger regenerating muscle fibers with centrally located nuclei. Knockdown of IL8 in FECS-Ad decreased the area and size of regenerating muscle fibers.
conclusionsOur findings underscore the dual role of IL8 in safeguarding muscle tissues from degeneration and orchestrating immunomodulatory effects by finely tuning tissue inflammation and macrophage polarization. This study highlights IL8 as a pivotal paracrine factor contributing to tissue regeneration in the context of stem cell therapy for CLI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.